Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738902 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL16803412 | 0.93 | ALDH1A1 (0.37) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL14304158 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL10028746 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL764579 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL740264 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL30195631 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL740263 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL737432 | 0.81 | ALDH1A1 (0.35) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL737430 | 0.81 | ALDH1A1 (0.35) | ALDH1A1CHRNB2CHRNA4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266631-B2 | Method for preparing peptide-polymer conjugate with stabilized α-helix secondary structure and peptide-polymer conjugate prepared thereby | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2019-04-23 | — | — | US | disclosed |
| EP-2049488-B1 | N'-CYANO-N-ALKYL HALIDE IMIDE AMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-12-09 | — | — | EP | disclosed |
| EP-2569023-B1 | GLYCEROL ESTER ACTIVE AGENT DELIVERY SYSTEMS AND METHODS | SURMODICS INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8871819-B2 | Glycerol ester active agent delivery systems and methods | SURMODICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8138350-B2 | N′-cyano-N-halogenalkylimidamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138350-B2 | N′-cyano-N-halogenalkylimidamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20110275725-A1 | GLYCEROL ESTER ACTIVE AGENT DELIVERY SYSTEMS AND METHODS | BANK OF MONTREAL, AS COLLATERAL AGENT | 2011-11-10 | — | — | US | disclosed |
| US-20100048646-A1 | N'-Cyano-N-Halogenalkylimidamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048646-A1 | N'-Cyano-N-Halogenalkylimidamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-5599453-A | POROUS MINERAL OXIDE SUBSTRATE MATRIX, THREE-DIMENSIONAL POLYMER GEL NETWORK; FOR SEPARATION OF BIOMOLECULES | BIOSEPRA INC. (US) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275725-A1 | GLYCEROL ESTER ACTIVE AGENT DELIVERY SYSTEMS AND METHODS | GK, LIPA, LIPE | ALDH1A1 559/4885CHRNB2 4628/4885CHRNA4 4572/4885 |
| US-20100048646-A1 | N'-Cyano-N-Halogenalkylimidamide Derivatives | NCLN, NISCH, DDT | ALDH1A1 3834/4885CHRNB2 729/4885CHRNA4 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.